Technical Analysis for FTSV - Forty Seven, Inc.

Grade Last Price % Change Price Change
grade F 12.54 2.03% 0.25
FTSV closed up 2.03 percent on Tuesday, May 21, 2019, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical FTSV trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 2.03%
Calm After Storm Range Contraction 2.03%
Lower Bollinger Band Walk Weakness 2.03%
Inside Day Range Contraction 2.03%

Older signals for FTSV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
Medicine Cancer Medical Specialties Immunology Cancers Monoclonal Antibodies Cancer Immunotherapy Ovarian Cancer Lymphoma Acute Myeloid Leukemia Cancer Research Humanized Antibody NHL CD47
Is FTSV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.83
52 Week Low 10.5
Average Volume 209,995
200-Day Moving Average 15.6321
50-Day Moving Average 17.1858
20-Day Moving Average 16.9955
10-Day Moving Average 15.483
Average True Range 1.4269
ADX 29.19
+DI 8.1477
-DI 35.3462
Chandelier Exit (Long, 3 ATRs ) 15.3893
Chandelier Exit (Short, 3 ATRs ) 14.7807
Upper Bollinger Band 21.8702
Lower Bollinger Band 12.1208
Percent B (%b) 0.04
BandWidth 57.364597
MACD Line -1.2723
MACD Signal Line -0.5185
MACD Histogram -0.7538
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.38
Resistance 3 (R3) 13.36 13.05 13.24
Resistance 2 (R2) 13.05 12.84 13.07 13.19
Resistance 1 (R1) 12.80 12.71 12.93 12.82 13.15
Pivot Point 12.49 12.49 12.56 12.51 12.49
Support 1 (S1) 12.24 12.28 12.37 12.26 11.93
Support 2 (S2) 11.93 12.15 11.95 11.89
Support 3 (S3) 11.68 11.93 11.84
Support 4 (S4) 11.70